SMMT
Summit Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 1
Consensus Rating "Strong Buy"
Ample Liquidity
Significant Net Income Decline
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About SMMT
Summit Therapeutics Inc.
An UK developer of novel medicines for the treatment of Clostridium difficile infection
601 Brickell Key Drive, Suite 1000, Miami, FL 33131
--
Summit Therapeutics Inc., a Delaware corporation (" New Summit "), was incorporated in England and Wales on November 22, 2013 and has become a follow-on issuer to the Company. The Company is a biopharmaceutical company focused on the discovery, development and commercialization of patient, physician, caregiver and socially friendly drug therapies designed to improve quality of life, extend potential lifespan, and address serious unmet medical needs. The company's pipeline of product candidates is designed to be patient-friendly, new-age standard of care in the field of oncology therapy.
Earnings Call
Q1/2025
Estimate EPS-0.092911
Actual EPS-0.07
Estimate Revenue--
Actual Revenue0
Summit Therapeutics' Q1 2025: Key Contradictions on HARMONi-2 OS Data, Approval Strategy, and Trial Enrollment
May 06,2025 06:36
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
SMMT has released its 2025 Q3 earnings. EPS was reported at -0.13, versus the expected -0.05368, missing expectations. The chart below visualizes how SMMT has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
